Literature DB >> 17030053

Twentieth century toxinology and antivenom development in Australia.

Kenneth D Winkel1, Peter Mirtschin, John Pearn.   

Abstract

It was not until the last decade of the 19th century that an experimental approach (led by Bancroft in Queensland and Martin in Sydney and Melbourne) brought a higher plane of scientific objectivity to usher in the modern era of Australian toxinology. This Australia era, 1895-1905, coincided with and in some respects was the result of the new knowledge emerging from Europe and the Americas of the therapeutic effects of antitoxins. The subsequent systematic study of Australian venoms and toxins through to the 1930s and beyond, by Tidswell, Fairley, Ross, Kellaway and Cleland, set the foundation for Australia's leading reputation in venom research. As elsewhere, this development was to revolutionise the medical management of those victims who in the past had died in Australia from our venomous and toxic fauna. Morgan, Graydon, Weiner, Lane and Baxter at the Commonwealth Serum Laboratories emphasised the importance of cooperation between those expert at catching and milking the venomous creatures and those developing the antivenoms. Commercial antivenom manufacture began in Australia in 1930 with the tiger snake antivenom. This was followed by other antivenoms for the other important species (1955: taipan; 1956: brown snake; 1958: death adder; 1959: Papuan black snake; 1961: sea snake; 1962: polyvalent) including the first marine antivenoms in the world (1956: stonefish antivenom; 1970: box jellyfish) culminating, in 1980, with the release of the funnel web spider antivenom. More recent activity has focused on veterinary antivenoms and production of new generation human antivenoms for export (CroFab and ViperaTAB). This paper reviews some of the milestones of Australian toxinology, and antivenom development in particular, during the 20th century.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17030053     DOI: 10.1016/j.toxicon.2006.08.001

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  Consequences of neglect: analysis of the sub-Saharan African snake antivenom market and the global context.

Authors:  Nicholas I Brown
Journal:  PLoS Negl Trop Dis       Date:  2012-06-05

2.  Severe anaphylactic reaction to mediterranean jellyfish (Ropilhema nomadica) envenomation: Case report.

Authors:  Nadav Friedel; Dennis Scolnik; Dikla Adir; Miguel Glatstein
Journal:  Toxicol Rep       Date:  2016-03-15

Review 3.  History of Envenoming Therapy and Current Perspectives.

Authors:  Manuela B Pucca; Felipe A Cerni; Rahel Janke; Erick Bermúdez-Méndez; Line Ledsgaard; José E Barbosa; Andreas H Laustsen
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

4.  Preparation and Neutralization Efficacy of Novel Jellyfish Antivenoms against Cyanea nozakii Toxins.

Authors:  Rongfeng Li; Huahua Yu; Aoyu Li; Chunlin Yu; Pengcheng Li
Journal:  Toxins (Basel)       Date:  2021-02-21       Impact factor: 4.546

Review 5.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.